Skip to content
Calculator
Guide

Epitalon and telomeres: what the studies actually measured

Last updated: November 4, 2026 · 6 min read · By the Grey Peptides Editorial Board

Scientist measuring bacteria growth in petri dishes under sterile lab conditions
Photo by Thirdman on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Every telomere result for epitalon comes from cells in a dish. No published study has measured telomeres in people who took it.
  • The animal results cited here are modest and come from the developer's group and its collaborators; the biggest lifespan and human figures come from epithalamin, a cattle pineal extract, not the synthetic peptide.
  • FDA reviewers found no clinical studies assessing its safety and called the mouse genotoxicity and tumour studies too limited to inform its cancer risk. The compounding committee recommended it anyway in July 2026; as of October 27, 2026 the FDA had not acted on the vote.

A four-amino-acid peptide and a big claim

Epitalon Low, also spelled epithalon, is a tetrapeptide: alanine, glutamic acid, aspartic acid and glycine, AEDG. It was synthesized from the amino-acid composition of epithalamin, an extract of cattle pineal gland; a 2025 review of 25 years of research on it says it remains uncertain whether the mechanisms found so far are its only ones, and that physical and structural studies of the peptide are few 1. The founding telomere paper and the one report in patients below come from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology 2 3. Wellness clinics market it online as an anti-ageing agent on the claim that it increases telomerase, FDA reviewers noted in 2026 4. Telomeres are the protective ends of chromosomes; they shorten as cells divide, and a cell whose telomeres reach a critical length stops dividing 4.

What the cell studies measured

The founding result, in 2003, was in human fetal fibroblasts that do not normally make telomerase. Adding epitalon to the culture switched on the gene for telomerase's catalytic subunit, produced measurable telomerase activity and lengthened telomeres 2. A 2025 study repeated the idea in normal human epithelial cells and fibroblasts and found dose-dependent telomere lengthening through more hTERT and telomerase. It also treated two breast-cancer cell lines, and their telomeres grew too, through a telomerase-independent route called ALT 5. In stimulated blood lymphocytes from 11 men, incubated with the peptide by Khavinson's group, relative telomere length changed significantly in 7: it rose in five, by 18% to 156%, and fell in two, by 15% and 37%; the authors saw a tendency for short telomeres to lengthen and long ones to shorten 6. The 2025 study, from Brunel University London, is the one independent group here 5.

These are real measurements, but of cells in a dish exposed directly to the peptide. They do not show what happens to telomeres in a person who injects it, and the breast-cancer result is a reason for caution as much as for interest: FDA reviewers made the same point in 2026: longer telomeres are generally associated with a higher cancer risk, so epitalon has the potential to be carcinogenic from the mechanistic standpoint 4.

What the animal studies measured

In the longest mouse study, 54 female mice received epitalon five days a month from three months of age until death and 54 received saline. Average lifespan did not change; the longest-lived 10% lived 13.3% longer and maximum lifespan rose 12.3% 7. In mice bred to develop HER-2/neu breast cancer, injections five times a week raised average lifespan by 13.5% and made tumour-free mice 3.7 times more common 8, and in another strain fewer treated mice developed malignant tumours 9. These studies come from the developer's group and its collaborators, and none measured telomeres in the animals as the outcome.

What was measured in people, and in what

The human evidence is thin, and much of it is about a different product. The largest human study, a 12-year randomised trial in elderly heart patients reporting 28% fewer deaths, used epithalamin, the pineal extract, not synthetic epitalon, and was co-authored by Khavinson 10. Lifespan gains of 11% to 31% across fruit flies, mice and rats also come from the extract 11. For the synthetic peptide, one paper reports rats with inherited retinal degeneration and then a positive effect in 90% of treated patients; its abstract gives no patient count and no detail of any comparison 3. FDA's reviewers found one more: a 2021 randomised, placebo-controlled study in which 40 women aged 40 to 50, mostly night-shift workers with low melatonin output, took sublingual AEDG or placebo for 20 days; a urinary melatonin metabolite rose 1.7-fold with the peptide and not with placebo. FDA noted that blinding was not stated, the study was small and short, and it measured no sleep outcome 4. It did not measure telomeres.

So the claim that epitalon lengthens telomeres in people rests on no measurement in people at all. It is an extrapolation from cell cultures.

What FDA reviewers found, and the vote

When the FDA's compounding committee considered epitalon in July 2026, agency staff evaluated it for insomnia, the use nominated. They found no clinical studies assessing its safety in people, no adverse-event reports in FAERS and no pharmacokinetic data. Its genotoxicity record was two chromosome-aberration studies and one micronucleus study in mice, none showing more damage, and its tumour record three similar mouse studies from one research group; FDA judged them too limited (one fixed dose, female mice only, short exposure) to inform its genotoxic or cancer potential, found no 2-year carcinogenicity study, and concluded that the balance of criteria weighed against listing it 4. The committee voted on July 24, 2026 to recommend adding it to the 503A list anyway; published reports put the tally at 7 to 4 or 7 to 5 with one abstention 12 13. FDA has posted no minutes or tally, and on October 27, 2026 its 503A categories list (updated May 14, 2026) did not include epitalon in any category 13. Our guide to peptides and cancer sets the telomerase question beside the other cancer worries.

On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of epitalon under the forms, routes and conditions in its Appendix B 14. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

Frequently asked questions

Does epitalon lengthen telomeres?

In cultured human cells, yes: it switched on telomerase and lengthened telomeres in fibroblasts and other cells. No published study has measured telomeres in people who took it.

What are epitalon's proven benefits in humans?

None established. The 12-year study reporting fewer deaths used epithalamin, a cattle pineal extract. For the peptide itself there is a retinal report whose abstract gives no patient count and a 20-day study in 40 women that measured a melatonin metabolite, not a health outcome or telomeres.

Is epitalon a cancer risk?

Unknown. It lengthened telomeres in two breast-cancer cell lines, and FDA reviewers judged the mouse genotoxicity and tumour studies, all from one group, too limited to inform its cancer potential, noting that telomerase activation is itself a concern.

Has FDA acted on the committee's vote?

Not as of October 27, 2026. The compounding committee recommended epitalon in July 2026, but FDA's 503A categories list (updated May 14, 2026) does not include it, and FDA's own briefing had weighed against listing it.

Sources

  1. Araj, S. K., et al. (2025). Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci, 26(6). PMID: 40141333
  2. Khavinson, V. K. h., et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med, 135(6), 590-2. PMID: 12937682
  3. Khavinson, V., et al. (2002). Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett, 23(4), 365-8. PMID: 12195242
  4. US Food and Drug Administration (2026). FDA Briefing Document for Epitalon-Related Bulk Drug Substances (epitalon free base and epitalon acetate), Pharmacy Compounding Advisory Committee, July 24, 2026; linked from the meeting page (content current as of August 6, 2026); read in full October 27, 2026. FDA briefing document
  5. Al-Dulaimi, S., et al. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), 178. PMID: 40908429
  6. Khavinson, V. K., et al. (2019). Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes. Bull Exp Biol Med, 168(1), 141-144. PMID: 31761987
  7. Anisimov, V. N., et al. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193-202. PMID: 14501183
  8. Anisimov, V. N., et al. (2002). Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bull Exp Biol Med, 134(2), 187-90. PMID: 12459848
  9. Kossoy, G., et al. (2006). Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo, 20(2), 253-7. PMID: 16634527
  10. Korkushko, O. V., et al. (2006). Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med, 142(3), 356-9. PMID: 17426848
  11. Anisimov, V. N., et al. (1998). Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats. Mech Ageing Dev, 103(2), 123-32. PMID: 9701766
  12. McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus). Cited without a link.
  13. US FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026: briefing documents; no minutes or vote tallies posted (content current as of August 6, 2026); 503A list (updated May 14, 2026) re-read October 27, 2026: none of the six recommended peptides in Category 1. FDA
  14. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead